Recurrent Glioblastoma: Where we stand

Area of Science:

• Neuro-oncology
• Cancer Therapeutics
• Clinical Decision-Making

Background:

• Glioblastoma (GBM) treatment combines surgery and chemoradiation, offering marginal survival gains.
• Patient age alone should not exclude GBM treatment; performance status is a critical factor in planning.
• Recurrent GBM is common despite aggressive initial therapy, requiring diverse treatment strategies.

Purpose of the Study:

• To review current glioblastoma treatment paradigms.
• To highlight the importance of performance status in treatment decisions.
• To explore emerging therapeutic strategies for recurrent glioblastoma.

Main Methods:

• Literature review of current and investigational glioblastoma therapies.
• Analysis of treatment guidelines and clinical trial data.
• Discussion of challenges in glioblastoma management.

Main Results:

• First-line GBM treatment involves surgical resection and chemoradiation.
• Performance status significantly influences treatment planning and outcomes.
• Recurrent GBM management includes re-resection, chemotherapy, reirradiation, and novel agents.

Conclusions:

• Glioblastoma remains an aggressive malignancy requiring multimodal treatment approaches.
• Further research into GBM pathophysiology is essential for developing more effective therapies.
• Novel therapeutic avenues include immunotherapy, gene therapy, and targeted agents.